Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer

Overview of attention for article published in Annals of Surgery, September 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter: 32 X users

guideline: 2 clinical guideline sources

Readers on

mendeley: 116 Mendeley

So far, Altmetric has seen 39 X posts from 32 X users, with an upper bound of 201,982 followers.

RT @DrJashDatta: @PeterHoseinMD @SyedAAhmad5 @DavendraSohal @rachnatshroff @CathyEngMD @pashtoonkasi @mkatzmd @NirajGusani @NbMerchant @Syl…

RT @SyedAAhmad5: Another great paper from our Central Pancreas Consortium group. @AHPBA @IHPBA @Shrikhande_SV @MarcBesselink @NirajGusani @…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 35 additional X posts.